Johnson & Johnson beats estimates, raises guidance

Shares of Johnson & Johnson (JNJ) are up 1.8% premarket following the company's top and bottom line Q3 beat.

Domestic sales rise 1.7% for the quarter, while international sales jump 4.2%.

Diluted EPS +8.8% Y/Y.

Global consumer sales come in at $3.6B, up 2% Y/Y ex-currency impact.

Global pharmaceutical sales rise 10.9% (ex-currency impact) to $7B.

Worldwide medical devices sales of $6.9B rise slightly, but fall when adjusted for a negative currency impact of 2.3%.

FY13 EPS guidance raised to $5.44-5.49 from $5.40-5.47. Consensus is $5.46. (PR)

From other sites
Comments (1)
  • Dividend Garden
    , contributor
    Comments (489) | Send Message
    Excellent results, JNJ.
    15 Oct 2013, 10:02 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs